Meniere’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Ménière's disease, a disorder affecting the inner ear, brings about intense vertigo, tinnitus (ringing in the ears), hearing impairment, and a sensation of ear fullness or congestion. Typically confined to one ear, Ménière's disease can prompt abrupt dizzy spells or follow a brief period of tinnitus or muted hearing. Some individuals experience isolated dizzy episodes, widely spaced in time, while others encounter clusters of attacks over consecutive days. For certain sufferers, the vertigo is so intense that it leads to loss of balance and falls, referred to as "drop attacks." The root cause of Ménière's disease remains elusive, but its symptoms can be attributed to excessive fluid within the inner ear. The fluid buildup might result from excessive production or inadequate absorption. Allergies or autoimmune disorders might contribute, especially in cases affecting both ears. Occasionally, other conditions can mimic Ménière's disease symptoms. Common manifestations of Ménière's disease encompass:
- Episodes of dizziness or vertigo, characterized by a sensation of spinning
- Hearing loss
- Tinnitus, perceived as roaring, buzzing, or ringing in the ear
- Feeling of ear fullness in the affected ear
- Symptom co-occurrence
Ménière's disease is a multifaceted and varied disorder where numerous factors interact, such as anatomical differences in the temporal bone, genetics, autoimmunity, migraines, inner ear fluid dynamics changes, and cellular and molecular mechanisms. Though Ménière's disease lacks a definitive cure, vertigo attacks can be effectively managed in nearly all cases. Treatment possibilities comprise:
- Adopting a low-sodium diet along with diuretic medication
- Usage of anti-vertigo drugs to halt acute attacks
- Intratympanic administration of dexamethasone or gentamicin
- Surgical intervention
The onset of Ménière's disease can occur at any age, with a higher likelihood between 40 and 60 years old. The National Institute on Deafness and Other Communication Disorders (NIDCD) approximates that around 615,000 individuals in the United States are diagnosed with Ménière's disease, with 45,500 new cases being identified annually.
Thelansis’s “Meniere’s Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Meniere’s Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Meniere’s Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Meniere’s Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment